Completed EARLY_PHASE1 INTERVENTIONAL 2-arm NCT04256733

Cough Desensitization Therapy for Cough Hypersensitivity Syndrome

A Pilot Study of Cough Reflex Desensitization for the Treatment of Cough Hypersensitivity Syndrome

Sponsor: University of Montana

Conditions Cough

Interventions Sub-threshold doses of diluted capsiacin via a KoKo Digidoser nebulizer Supra-threshold and progressive doses of diluted capsaicin via a Koko Digidoser nebulizer

Updated 7 times since 2020 Last updated: Aug 3, 2023 Started: May 1, 2019 Primary completion: Nov 30, 2020 Completion: Feb 13, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This EARLY_PHASE1 trial investigates Cough and is currently completed. University of Montana leads this study, which shows 7 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed EARLY_PHASE1
Apr 2024 — Jul 2024 [monthly]

Completed EARLY_PHASE1
Apr 2021 — Apr 2024 [monthly]

Completed EARLY_PHASE1

Status: Recruiting → Completed · Phase: PHASE1 → EARLY_PHASE1
Jan 2021 — Apr 2021 [monthly]

Recruiting PHASE1

▶ Show 2 earlier versions

Dec 2020 — Jan 2021 [monthly]

Recruiting PHASE1
Mar 2020 — Dec 2020 [monthly]

Recruiting PHASE1

First recorded

May 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Montana

Data source: University of Montana

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Missoula, United States